PLANT & INFRASTRUCTURENo sanctions match · screened 20 Nov 2026
Medtronic
medtronic.comUpdated 8 Nov 2026
Strategic intent
Medtronic is a global healthcare technology company that designs, manufactures, and distributes medical devices and therapies across cardiovascular, neuroscience, and surgical portfolios.
Key market signals
- 2026-11: Medtronic received FDA approval for a labeling update to its Symplicity Spyral renal denervation (RDN) system, expanding clinical evidence to include patients with isolated systolic hypertension, chronic kidney disease, and type 2 diabetes.
- 2026-11: Medtronic partnered with The Michael J. Fox Foundation for Parkinson's Research to launch a new educational initiative to expand awareness of deep brain stimulation (DBS) therapy.
- 2026-10: Medtronic completed the full separation of its diabetes business, MiniMed Group, Inc. (Nasdaq: MMED), via a 5.4x oversubscribed exchange offer, leaving Medtronic with no remaining equity stake.
- 2026-09: Medtronic announced a strategic partnership and approximately $700 million investment in Hong Kong-based Cornerstone Robotics, securing rights to distribute its Sentire surgical system outside the US.
- 2026-07: Medtronic completed its $650 million cash acquisition of SPR Therapeutics, adding the SPRINT percutaneous peripheral nerve stimulation (PNS) system to its neuromodulation pain therapy portfolio.
Financial health
- For the fiscal year 2026 ended April 24, 2026, Medtronic reported worldwide revenue of $36.364 billion, representing an 8.4% increase as reported and 5.8% organic growth (https://news.medtronic.com).
- FY26 GAAP diluted EPS was $3.73 (up 3.3% year-over-year) and non-GAAP diluted EPS was $5.53 (up 0.7% year-over-year) (https://news.medtronic.com).
- FY26 cash from operations grew 4.1% to $7.330 billion, and free cash flow increased 4.6% to $5.426 billion (https://news.medtronic.com).
Impact & compliance
Social ImpactModern Slavery Statement (2026)Scope 3 data: comprehensiveThird-party assured
Forensic audit
- Aug 2026: In August 2026, a federal jury in Ohio returned an $88 million verdict against Medtronic's Covidien unit in Patterson v. Covidien, the first federal bellwether trial over Covidien hernia mesh defects.
Proprietary analysis
- Log in to see
Strategic fit
AI-calculated strategic alignment score
- Log in to see
Cultural fit
Trust and integrity score
- Log in to see
Alignment dimensions
How this supplier scores against each of your strategic imperatives
- Log in to see
Full forensic analysis
Complete ESG audit, modern slavery risk assessment, labour sentiment analysis, and observed contradictions with evidence trails.
Want the full analysis?
Strategic and cultural fit scoring, full forensic detail and alignment dimensions, for this supplier and your own.